BioSpace News Archive

Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of February.

Strong growth and pipeline momentum with three new medicines approved since the third quarter

The MODIA® study didn’t meet the primary end-points, but showed high rates of treatment response in both study arms, with no adverse events associated with the use of MODIA.

XNK Therapeutics AB announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.

Vandria SA announced that it has been awarded two grants totalling €3.8M from Innosuisse and Eurostars to support its two lead drug candidates addressing CNS and muscle diseases, respectively.

RaySearch Laboratories AB is proud to announce that The Royal Marsden NHS Foundation Trust, a specialist cancer center in the UK, will be the first in the world to implement online adaptive radiation therapy with RaySearch’s treatment planning system RayStation®* and oncology information system RayCare®* - including the new ARTemis* OART solution under development - in combination with the Radixact® Treatment Delivery System from Accuray.

Swedish Orphan Biovitrum AB announced its report for the fourth quarter 2023.

We have successfully dosed the first of three patients in Cohort 8, the last cohort of the Phase 1 dose-ranging part of the Phase 1/2 clinical trial in newly diagnosed uMGMT Glioblastoma Multiforme patients.

Closed Loop Medicine Ltd. announced the publication of a peer-reviewed study in the Journal of the American Heart Association .

BioNTech SE and Autolus Therapeutics plc announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations.